RxDoctor Payments Data

Yasir Taha, MD

Interventional Cardiology · Atlanta, GANPI 1083928279

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Edwards Lifesciences at 43.7% of the total. Reporting peaked in 2021 at $1,675 and has fallen 86.4% since, to $228 in 2025. That places this record below the midpoint for interventional cardiology clinicians in GA, where the typical reported total is $7,640.

$2,668in general payments, 2019–2025

Across 44 payments — averaging $60.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Boston Scientific$502
  • Bard Peripheral Vascular, Inc.$291
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$119
  • Stryker$116
  • Cardiovascular Systems Inc.$99
  • plus $376 from 11 others
$62,272in research payments, 2019–2025

Across 3 payments — averaging $20,757 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$62K

What the payments were for

  • Travel & lodging$68926%
  • Food & beverage$1,40153%
  • Education$57822%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,668 in reported general payments places this provider in the 15th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$16,701
Medicare patients
135
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol14$18,734
Metoprolol Succinate17$359
Rosuvastatin Calcium13$141
Carvedilol11$86
Spironolactone15$77
Furosemide18$47

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →